Relmada Therapeutics (RLMD) Enterprise Value (2014 - 2026)

Relmada Therapeutics (RLMD) has reported Enterprise Value for 15 consecutive years, with -$234.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Enterprise Value fell 764.58% year-over-year to -$234.0 million; the TTM figure through Mar 2026 stood at -$234.0 million (down 764.58% YoY), while the FY2025 annual figure was -$93.0 million, down 107.1% from the prior year.
• Enterprise Value eased to -$234.0 million in Q1 2026 per RLMD's latest filing, from -$93.0 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$13.9 million in Q3 2025 and bottomed at -$234.0 million in Q1 2026.
• Historically, Enterprise Value has averaged -$109.4 million across 5 years, with a median of -$96.3 million in 2023.
• Annual changes were most pronounced in 2025 — Enterprise Value surged 74.34% — and 2026, when it tumbled 764.58%.
• Relmada Therapeutics' Enterprise Value stood at -$148.3 million in 2022, then soared by 35.06% to -$96.3 million in 2023, then surged by 53.38% to -$44.9 million in 2024, then plunged by 107.1% to -$93.0 million in 2025, then tumbled by 151.56% to -$234.0 million in 2026.
• Business Quant data shows RLMD's Enterprise Value at -$234.0 million in Q1 2026, -$93.0 million in Q4 2025, and -$13.9 million in Q3 2025.